PHE / Publications

All Publications

Date	Title
2013	Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes Formularies of the future should use evidence founded on findings from comparative effectiveness research (CER) to better target, not limit, diabetes care. In the case of diabetes, partially due to the fact that many cases require more than 1 medication, suboptimal management (i.e., lack of adhe ...
2013	Impact of Oral Nutritional Supplementation on Hospital Outcomes This study found that ONS use in hospitalized patients led to substantial reductions in length of stay, episode cost, and 30-day readmissions. Because ONS is inexpensive to provide, the sizable savings generated make it a cost-effective therapy. Given the high prevalence of malnutrition among in ...
2013	Spending and Mortality in US Acute Care Hospitals Spending on inpatient care appears to be efficacious in reducing mortality for common, acute medical conditions. This finding contrasts with evidence that US regions with higher Medicare spending do not have better quality of care. Inpatient spending is associated with lower mortality primarily ...
2013	On Average, Physicians Spend Nearly 11 Percent of Their 40-Year Careers With An Open, Unresolved Malpractice Claim The US malpractice system is widely regarded as inefficient, in part because of the time required to resolve malpractice cases. Analyzing data from 40,916 physicians covered by a nationwide insurer, we found that the average physician spends 50.7 months-or almost 11 percent-of an assumed forty-y ...
2013	Endogenous Cost-Effectiveness Analysis and Health Care Technology Adoption Increased health care spending has placed pressure on public and private payers to prioritize spending. Cost-effectiveness (CE) analysis is the main tool used by payers to prioritize coverage of new therapies. Jena and Philipson argue that reimbursement based on CE is subject to a form of the "L ...
2013	Medicare Payment Reform and Provider Entry and Exit in the Post-Acute Care Market Huckfeldt and co-authors sought to understand the impacts of Medicare payment reform on the entry and exit of post-acute providers. From 1991-2010, payment reforms reducing average and marginal payments, such as the Home Health Interim Payment System and the Skilled Nursing Facility Prospective ...
2013	Measuring the Value of Better Diabetes Management The growing burden of type 2 diabetes mellitus has outpaced the modest progress in the efficacy of diabetes medications. However, it is unclear whether existing medications are being used optimally. This article quantifies the value of addressing underuse of existing diabetes medications in the ...
2013	Hospital Value-based Purchasing Hospital value-based purchasing (VBP) aims to incentivize inpatient providers to deliver high value, as opposed to high volume, health care. The formal mandate of hospitals to provide high value health care through financial incentives marks an important change in Medicare and Medicaid policy. I ...
2012	Innovation and the Welfare Effects of Public Drug Insurance Prescription drug insurance is able to lower static deadweight loss without reducing incentives for innovation, with the result that the public provision of drug insurance can be welfare-improving, even for risk-neutral and purely self-interested consumers. The level of welfare improvement achie ...
2012	Book Review: Shredding the Social Contract: The Privatization of Medicare Perspective: Ultimately, Geyman’s personal diagnosis of the Medicare program makes for entertaining reading. Readers looking for innovative policy prescriptions, however, will need to go elsewhere.
2012	How Cancer Patients Value Hope and the Implications for Cost-Effectiveness Assessments of High-Cost Cancer Therapies 77 percent of surveyed cancer patients with melanoma, breast cancer, or other types of solid tumors preferred hopeful gambles to safe bets. This suggests that current technology assessments, which often determine access to such cancer therapies, may be missing an important source of value to pat ...
2012	Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates Patients place high valuations on metastatic cancer therapy, on average, twenty-three times higher than its cost. Our methods provide another framework for an evidence-based approach to assessing the value of treatment for terminal illness.
2012	Outcomes of Medical Malpractice Litigation against U.S. Physicians In this study approximately 50% of all malpractice claims involved litigation, with half of these litigated claims being dismissed in court. The substantial portion of litigated claims that are not dismissed in court and the length of time required to resolve litigated claims more generally may ...
2012	Intellectual Property and Marketing in the Pharmaceutical Industry The authors find that pharmaceutical patent expirations empirically lower output by 5 percent in the short-run, due to post-expiration reduction in marketing. In the long-run, expirations still raise output. However, the value of monopoly marketing to consumers —excluding value to firms — ...
2012	An Analysis of Whether Higher Health Care Spending in the United States versus Europe Is ‘Worth It’ in the Case of Cancer U.S. cancer patients have greater survival gains than their European counterparts, indicating that higher U.S. costs might, in fact, be cost-effective. Even after considering higher US costs, this investment generated $598 billion of additional value for US patients who were diagnosed with cance ...
2012	Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products Intellectual property rights are viewed as essential to medical innovation, but very often involve social costs due to patent monopolies and other inefficiencies. The authors discuss how intellectual property can be used to solve a variety of production externalities that afflict health care, in ...
2012	Incentives to Innovate Efficient innovation policy requires that we decouple the innovator’s private rewards from consumer prices and instead tie them to the marginal social value of the invention. This is not easy to achieve, but movement toward this goal can be effected through a mix of policy instruments.
2012	How Cancer Patients Value Hope and the Implications for Cost-Effectiveness Assessments of High-Cost Cancer Therapies 77 percent of surveyed cancer patients with melanoma, breast cancer, or other kinds of solid tumors preferred hopeful gambles to safe bets. This suggests that current technology assessments, which often determine access to such cancer therapies, may be missing an important source of value to pat ...
2012	Survey Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs A survey of healthy adults found that they were willing to pay an extra $12.94 on average in insurance premiums per month for generous specialty-drug coverage—in effect, $2.58 for every dollar in out-of-pocket costs that they would expect to pay with a less generous insurance plan.
2012	Expenditures for Medicaid Patients Treated With Exenatide Compared with Other Diabetes Management Regimens Medicaid data from 2005-2009 suggest that type 2 diabetes mellitus (T2DM) patients given exenatide, a glucagon-like-peptide-1 receptor agonist, had reduced costs compared with those given a thiazolidinedione, basal insulin, or a dipeptidyl peptidase-4-inhibitor. Additionally, these results indic ...
2012	Value of Survival Gains in Chronic Myeloid Leukemia This study estimated a 90-month treatment-on-the-treated survival rate of 65% after the introduction of imatinib in 2001. Cost analyses indicate that the tyrosine kinase inhibitor (TKI) drug class in chronic myeloid leukemia (CML) therapy has created more than $143 billion in social value. Appro ...
2012	The Disability Burden of COPD Affecting an estimated 12.6 million people and causing over 100,000 deaths per year, chronic obstructive pulmonary disease (COPD) exacts a heavy burden on American society. Controlling for initial health status and a variety of sociodemographic factors, we find that COPD causes people to be 20% ...
2012	Inhaled Corticosteroids and the Risk of Pneumonia in Medicare Patients with COPD When chronic obstructive pulmonary disease (COPD) patients remain at increased risk of exacerbations despite the use of a combination of one or more long-acting bronchodilator with a short-acting bronchodilator, physicians are encouraged to prescribe an inhaled corticosteroid (ICS), in conjuncti ...
2012	The Option Value of Innovative Treatments in the Context of Chronic Myeloid Leukemia Traditional health-technology assessment, such as cost-effectiveness analysis, measures the value of a health innovation by comparing benefits (eg, survival gains or improved quality of life) to costs, assuming no further improvements in medical technology aside from the innovation in question. ...
2012	Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population Postmarketing reports have linked exenatide use with acute pancreatitis and pancreatic cancer, but a definitive relationship has yet to be established. Romley and co-authors used claims from 2007-2009 in a US administrative database of 268,561 privately insured individuals and found that, consis ...
2012	Cost-Sharing and Initiation of Disease-Modifying Therapy for Multiple Sclerosis While cost-sharing for pharmaceuticals has been proposed as a means of controlling health spending, it can reduce the use of therapy by patients. This study examines the association between cost-sharing and initiation of disease-modifying therapies (DMTs) among privately insured patients with mu ...
2012	Dynamic Cost-Effectiveness of Oncology Drugs The traditional approach to conducting cost-effectiveness analyses (CEAs) is that they are typically performed at the time of initial drug launch or for individual indications; therefore, such analyses often disregard the overall cost-effectiveness of a single agent in the longer run, which can ...
2012	The Value of Medical and Pharmaceutical Interventions for Reducing Obesity This paper attempts to quantify the social, private, and public-finance values of reducing obesity through pharmaceutical and medical interventions. Michaud and co-authors find that the total social value of bariatric surgery is large for treated patients, with incremental social cost-effectiven ...
2012	An Economic Analysis of Conservative Management versus Active Treatment for Men with Localized Prostate Cancer Comparative effectiveness research suggests that conservative management (CM) strategies are no less effective than active initial treatment for many men with localized prostate cancer. The present study estimates longer-term costs of initial management strategies and potential US health expendi ...
2012	Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia This study was designed to assess the effect of tyrosine kinase inhibitor (TKI) use on non-pharmaceutical medical spending for patients with chronic myeloid leukemia (CML) and estimate the association between cost-sharing and the TKI medication possession ratio (MPR). The retrospective study cov ...

Publications

All Publications

No matches found